What happened
DongKoo Bio & Pharma reported consolidated results for FY2025: revenue of US$162M (−2.6% year on year), operating profit of US$6.16M (−27.1% year on year) and net income of US$33.4M (+2420.2% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$162M |
|---|---|
| Revenue vs a year earlier | −2.6% |
| Operating profit | US$6.16M |
| Net income | US$33.4M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-16, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260316900654 → open original filing |
Source: DART. Information only, not investment advice.